A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy

[1]  V. D. de Jesus,et al.  Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma. , 2018, Journal of gastrointestinal oncology.

[2]  M. Reni,et al.  Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. , 2017 .

[3]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  C. Bassi,et al.  Clinical Implications of the 2016 International Study Group on Pancreatic Surgery Definition and Grading of Postoperative Pancreatic Fistula on 775 Consecutive Pancreatic Resections , 2017, Annals of surgery.

[5]  C. Bassi,et al.  Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? , 2017, Annals of Surgical Oncology.

[6]  W. Scheithauer,et al.  nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial , 2017, OncoTargets and therapy.

[7]  M. Büchler,et al.  Radical surgery of oligometastatic pancreatic cancer , 2016 .

[8]  M. Reni,et al.  Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  M. Weinstein,et al.  Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  elliot k fishman,et al.  Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis , 2016, Journal of Gastrointestinal Surgery.

[11]  C. Dervenis,et al.  Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features. , 2016, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[12]  L. Wood,et al.  Pancreatic cancer , 2016, The Lancet.

[13]  J. Izbicki,et al.  Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. , 2016, Surgery.

[14]  B. Erickson,et al.  Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. , 2016, Surgery.

[15]  M. Büchler,et al.  Postoperative pancreatic fistula: We need to redefine grades B and C. , 2016, Surgery.

[16]  E. Fishman,et al.  Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns , 2015, Oncotarget.

[17]  H. Zeh,et al.  The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas , 2015, Journal of surgical oncology.

[18]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[19]  P. Neuhaus,et al.  The Impact of Simultaneous Liver Resection for Occult Liver Metastases of Pancreatic Adenocarcinoma , 2012, Gastroenterology research and practice.

[20]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[21]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[22]  M. Falconi,et al.  Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[23]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[24]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.

[25]  M. Reni,et al.  A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) , 2011, Cancer Chemotherapy and Pharmacology.

[26]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.